Seizure Prophylaxis for Acute Subdural Hematomas
Seizure prophylaxis should be considered for acute subdural hematomas (aSDH) with high-risk features: GCS <9, associated intracerebral hemorrhage, midline shift, or requiring craniotomy—but NOT for chronic subdural hematomas without these features.
Risk Stratification Approach
The decision for seizure prophylaxis in subdural hematomas depends critically on whether the hematoma is acute versus chronic, and the presence of specific high-risk characteristics.
High-Risk Features Requiring Prophylaxis (Acute SDH)
Based on the most recent evidence, prophylactic antiseizure medication is reasonable when ANY of the following are present 1, 2:
- GCS <9 (OR 10.5 for seizures) or GCS <12 at admission 1, 3
- Craniotomy/surgical evacuation (OR 3.9) 1, 2
- Associated intracerebral hemorrhage 2
- Midline shift present 1, 2
- Anticoagulation use (OR 2.2) 1
- Delayed surgery >24 hours (OR 2.0) 1
- Acute-on-chronic subdural hematoma (72.4% seizure incidence) 4
Low-Risk Features NOT Requiring Prophylaxis
Do NOT use prophylaxis for:
- Chronic subdural hematomas without acute bleeding (only 5.3% early seizure rate) 2
- Acute SDH with GCS ≥12-14 and no other risk factors 1, 3
- Small subdural hematomas ≤3mm without midline shift 5
Medication Selection
Levetiracetam is the preferred agent over phenytoin 6, 2. While both have similar efficacy for seizure prevention (OR 1.3), levetiracetam has significantly fewer adverse effects (OR 0.1) 6, 2. Phenytoin should be avoided due to drug interactions and worse cognitive outcomes 7.
Duration of Prophylaxis
The evidence from traumatic brain injury guidelines suggests prophylaxis should NOT be continued long-term 7. For patients undergoing surgery with high-risk features, consider prophylaxis for ≤7 days perioperatively, then discontinue if no seizures occur 7.
Critical Caveats
Important pitfall: The overall incidence of early seizures in acute SDH is 28%, but this drops to only 5.3% in chronic SDH 2. Many clinicians over-prescribe prophylaxis for chronic subdurals where the risk-benefit ratio does not support routine use.
Acute-on-chronic SDH is a special high-risk entity with 72.4% seizure incidence and 10.3% status epilepticus rate—these patients warrant strong consideration for prophylaxis 4.
The evidence does not support routine prophylaxis for all subdural hematomas 7. Instead, use the GATE-24 scoring approach: prophylaxis is recommended when GCS <14, **A**nticoagulation present, **T**reatment delayed >24 hours, or Evacuation via craniotomy 1.